Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for cancer. The company specializes in tumor-infiltrating lymphocyte, or TIL, therapies designed to use a patient’s own immune cells to recognize and attack solid tumors. Its product portfolio includes Amtagvi, an individualized T-cell therapy for advanced melanoma, and Proleukin, an interleukin-2 therapy used in oncology care. Iovance Biotherapeutics also maintains a broader clinical pipeline spanning multiple solid tumor indications, including cervical cancer, head and neck cancer, and other advanced cancers. Headquartered in San Carlos, California, Iovance Biotherapeutics plays a specialized role in the immunotherapy market by advancing personalized treatment approaches for patients with difficult-to-treat cancers.